KBC Group NV Increases Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

KBC Group NV raised its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 104.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,954 shares of the company’s stock after purchasing an additional 3,559 shares during the period. KBC Group NV’s holdings in Syndax Pharmaceuticals were worth $92,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. grew its stake in Syndax Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after purchasing an additional 541 shares during the last quarter. Northwestern Mutual Wealth Management Co. purchased a new position in Syndax Pharmaceuticals in the second quarter valued at about $27,000. Values First Advisors Inc. purchased a new position in Syndax Pharmaceuticals in the third quarter valued at about $30,000. Quantbot Technologies LP purchased a new stake in shares of Syndax Pharmaceuticals during the third quarter worth about $49,000. Finally, Creative Planning grew its stake in shares of Syndax Pharmaceuticals by 27.4% during the second quarter. Creative Planning now owns 18,428 shares of the company’s stock worth $378,000 after acquiring an additional 3,962 shares during the last quarter.

Syndax Pharmaceuticals Trading Down 1.9 %

Shares of NASDAQ:SNDX opened at $15.52 on Monday. Syndax Pharmaceuticals, Inc. has a 12-month low of $12.06 and a 12-month high of $25.34. The company has a market capitalization of $1.32 billion, a PE ratio of -4.28 and a beta of 0.90. The business has a 50 day moving average of $14.06 and a two-hundred day moving average of $17.40.

Wall Street Analysts Forecast Growth

SNDX has been the topic of a number of research analyst reports. UBS Group initiated coverage on Syndax Pharmaceuticals in a research note on Thursday, October 24th. They set a “buy” rating and a $37.00 price target on the stock. The Goldman Sachs Group lifted their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Citigroup lifted their target price on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, November 19th. Scotiabank decreased their target price on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. Finally, JPMorgan Chase & Co. lifted their target price on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an “overweight” rating in a report on Thursday, November 21st. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, Syndax Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.20.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).